Brain Fogvalethealth2023-10-02T21:59:55+00:00

Do you have menopause-related brain fog?

As women go through perimenopause and menopause, they often experience a range of symptoms, one of which is brain fog.

Brain fog can impact mental clarity, focus, and short-term memory.

Begin Brain Fog Questionnaire

Begin Brain Fog Questionnaire

1

Take our short survey to determine if some of the more common signs of brain fog may be affecting you.

Begin Brain Fog Questionnaire

If your score is 20 or more, you may be experiencing brain fog.

What is Brain Fog?

Brain fog during menopause occurs when the essential female hormone estrogen, abruptly declines.

Estrogen plays a multi-functional role in brain processing, synaptic connections, and the regulation of neurons that affect thinking and processing of information.

The decline in estrogen can lead to cognitive decline – brain fog.

Begin Brain Fog Questionnaire

2

If YOUR SCORE 20 OR HIGHER

Take our HealthFit online questionnaire to determine if PearlPAK™ may be right for you.

HIPAA-compliant, the questionnaire gathers information about your current health, to enable our board-certified telehealth practitioners to assess if PearlPAK™ is right for you.

3

AFTER THE HEALTH-FIT QUESTIONNAIRE

Continue to register for a free medical practitioner consultation.

After completing the questionnaire, you will be redirected to a page with insights on your responses and the next steps to schedule a free medical practitioner consultation.

Your payment information will be collected once you click to connect with the telehealth medical practitioner.

NO charges to your credit/debit card will be made unless you decide to sign up for PearlPAK. Regardless of your decision, the practitioner appointment remains complementary.

PearlPAK™ is designed specifically to treat menopause-related brain fog. It is not intended to treat neurological diseases including dementia or Alzheimer’s. If you are experiencing significant cognitive decline, contact your physician for an evaluation.

© Copyright 2023 CleopatraRX™. All Rights Reserved. View our Privacy Policy.

*PearlPAK™️ dose system is not intended to treat neurological diseases including dementia and Alzheimer’s Disease. It is specifically designed to target cognitive difficulties in perimenopause and early menopausal women only. If you are concerned about neurological disease or have a family history of neurological disease, contact your physician.

CleopatraRX™ and PearlPAK™ are trademarks of CleopatraRX Development, LLC. CleopatraRX™ is a service mark and is used throughout this website to represent the services offered by CleopatraRX Development, LLC. PearlPAK™ is a dosage product for use as a drug/routine system and/or treatment.

The PearlPAK™️ drug/routine system is protected by U.S. Patent No. 10,369,158 – PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY – which relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.

Estriol Therapy U.S. Patent No. 9,962,395 – COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION – Provides methods for reducing the progression of cognitive decline in a post-menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.

*PearlPAK™ dose system is not intended to treat neurological diseases including dementia and Alzheimer’s Disease. It is specifically designed to target cognitive difficulties in perimenopause and early menopausal women only. If you are concerned about neurological disease or have a family history of neurological disease, contact your physician.

CleopatraRX™ and PearlPAK™ are trademarks of CleopatraRX Development, LLC. CleopatraRX™ is a service mark and used throughout this website to represent the services offered by CleopatraRX Development, LLC. PearlPAK™ is a dosage product is for use as a drug/routine system and/or treatment.

The PearlPAK™ drug/routine system is protected by U.S. Patent No. 10,369,158 – PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY – which relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.

Estriol Therapy U.S. Patent No. 9,962,395 – COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION – Provides methods for reducing the progression of cognitive decline in a post – menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.